

1FW



Dkt. #639-B-PCT-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Nai-Kong CHEUNG

U.S. Serial No.: 10/621,027, continuation-in-part of
International Application No.
PCT/US02/01276, filed January 15, 2002,
claiming benefit of U.S. Serial No.
60/261,911, filed January 16, 2001

Filed Date : July 16, 2003

For : THERAPY-ENHANCING GLUCAN

Law Offices of Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, NY 11357

March 25, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant hereby submits this Supplemental Information Disclosure Statement in accordance with their duty of disclosure under 37 C.F.R. §1.56. Applicant originally filed an Information Disclosure Statement for the above-identified application on July 16, 2003 and Supplemental Information Disclosure Statements on April 12, 2004, September 24, 2004, November 8, 2004 and November 22, 2004. Applicant would like to direct the Examiner's attention to the following references which are listed below as **Exhibits 1-16** and on Form PTO/SB/08B (**Exhibit A**, 2 pages). A copy of the references cited in the International Search Report (**Exhibit 1**) will not be submitted because they were cited by the examiner in the December 17, 2004 non-final Office Action for the above-identified application. Further, Applicant's attorney's office may be contacted in the event that the Examiner would like a copy of all references filed with the July 16, 2003 Information Disclosure Statement, April 12, 2004 Supplemental Information Disclosure Statement, September 24, 2004,

Applicant : Nai-Kong CHEUNG
U.S. Serial No.: 10/621,027
Filed : July 16, 2003
Page : 2

November 8, 2004 and November 22, 2004 Supplemental Information Disclosure Statements.

The following references are attached:

1. PCT International Search Report for Sloan-Kettering Institute for Cancer Research, Int'l Application No. PCT/US04/23099, Filed July 16, 2004, Dated February 28, 2005 [Exhibit 1]
2. Babineau, T. et al., "Randomized Phase I/II Trial of a Macrophage-Specific Immunomodulator (PGG-Glucan) in High-Risk Surgical Patients", Annals of Surgery, Vol. 220, No. 5, Pages 601-609 (1994) [Exhibit 2]
3. Babineau, T. et al., "A Phase II Multicenter, Double-blind, Randomized, Placebo-Controlled Study of Three Dosages of an Immunomodulator (PGG-Glucan) in High Risk Surgical Patients", Arch Surg, Vol. 129, Pages 1204-1210 (1994) [Exhibit 3]
4. Arturson, G.; Wallenius, G., "The Renal Clearance of Dextran of Different Molecular Sizes in Normal Humans", Scandinaz J Clin & Lab Investigation, Vol. 1, Pages 81-86 (1964) [Exhibit 4]
5. Dellinger, E., et al., "Effect of PGG-glucan on the Rate of Serious Postoperative Infection or Death Observed After High-Risk Gastrointestinal Operations", Arch Surg, Vol 134, Pages 977-983 (1999) [Exhibit 5]
6. Arturson, G. et al., "Intravascular Persistence and Renal Clearance of Dextran of Different Molecular Sizes in Normal Children", Arch Dis Childh., Vol. 41, Pages 168-172 (1966) [Exhibit 6]

Applicant : Nai-Kong CHEUNG
U.S. Serial No.: 10/621,027
Filed : July 16, 2003
Page : 3

7. Sortwell, R. et al., "Chronic Intravenous Administration of Lentinan to the Rhesus Monkey", Toxicology Letters, Vol. 9, Pages 81-85 (1981) [Exhibit 7]
8. Shimazu, H. et al., "Intravenous chronic toxicity of lentinan in rats: 6-month treatment and 3-month recovery", National Library of Medicine (PubMed), J Toxicol Sci., Pages 33-57 (1980) [Exhibit 8]
9. Mehvar, R., "Recent Trends in the Use of Polysaccharides for Improved Delivery of Therapeutic Agents: Pharmacokinetic and Pharmacodynamic Perspectives", Current Pharmaceutical Biotechnology, Vol. 4, Pages 283-302 (2003) [Exhibit 9]
10. Hanaue, H. et al., "Basic Studies on Oral Administration of Lentinan (I)", J. Jpn. Soc. Cancer Ther., Vol. 8, Pages 1566-1571 (1989) [Exhibit 10]
11. Kidd, P., "The Use of Mushroom Glucans and Proteoglycans in Cancer Treatment", Alternative Medicine Review, Vol. 5, No. 1, Pages 4-27 (2000) [Exhibit 11]
12. Hanaue, H. et al, "Effects of Oral Lentinan on T-Cell Subsets in Periphel Venous Blood", Clinical Therapeutics, Vol. 5 (1989) [Exhibit 12]
13. Suzuki, M. et al, "Antitumor and Immunological Activity of Lentinan in Comparison with LPS", International Society for Pharmacology, Pages 463-468 (1994) [Exhibit 13]
14. Cheung, N.; Modak, S.; "Oral (1-3), (1-4)- β -D-Glucan Synergizes with Antiganglioside GD2 Monoclonal Antibody

Applicant : Nai-Kong CHEUNG
U.S. Serial No.: 10/621,027
Filed : July 16, 2003
Page : 4

3F8 in the Therapy of Neuroblastoma", Clinical Cancer Research, Vol. 8, Pages 1217-1223 (2002) [Exhibit 14]

15. Chihara, G. et al., "Antitumor and Metastasis-Inhibitory Activities of Lentinan as an Immunomodulator: An Overview", Cancer Detection and Prevention Supplement Vol. 1, Pages 423-443 (1987) [Exhibit 15]

16. Mayer, L.; Shao, L., "Therapeutic Potential of Oral Tolerance", Nature Reviews Immunology, Vol. 4, Pages 407-419 (2004) [Exhibit 16]

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.


I hereby certify that this paper is being deposited this date with the U.S. Postal Service with sufficient postage for first class mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Albert Wai-Kit Chan 3/25/05
Albert Wai-Kit Chan Date
Reg. No. 36,479

Respectfully submitted,

Albert Wai-Kit Chan

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicant
Law Offices of
Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357
Tel: (718) 357-8836
Fax: (718) 357-8615
E-mail: kitchanlaw@aol.com



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	Nai-Kong Cheung
Art Unit	1623
Examiner Name	Jason H. Johnsen
Attorney Docket Number	639-B-PCT-US

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	PCT International Search Report for Sloan-Kettering Institute for Cancer Research, Int'l Application No. PCT/US04/23099, Filed July 16, 2004, Dated February 28, 2005	
	2	Babineau, T. et al., "Randomized Phase I/II Trial of a Macrophage-Specific Immunomodulator (PGG-Glucan) in High-Risk Surgical Patients", Annals of Surgery, Vol. 220, No. 5, Pages 601-609 (1994)	
	3	Babineau, T. et al., "A Phase II Multicenter, Double-blind, Randomized, Placebo-Controlled Study of Three Dosages of an Immunomodulator (PGG-Glucan) in High Risk Surgical Patients", Arch Surg, Vol. 129, Pages 1204-1210 (1994)	
	4	Arturson, G.; Wallenius, G., "The Renal Clearance of Dextran of Different Molecular Sizes in Normal Humans", Scandiaz J Clin & Lab Investigation, Vol. 1, Pages 81-86 (1964)	
	5	Dellinger, E., et al., "Effect of PGG-glucan on the Rate of Serious Postoperative Infection or Death Observed After High-Risk Gastrointestinal Operations", Arch Surg, Vol 134, Pages 977-983 (1999)	
	6	Arturson, G. et al., "Intravascular Persistence and Renal Clearance of Dextran of Different Molecular Sizes in Normal Children", Arch Dis Childh., Vol. 41, Pages 168-172 (1966)	
	7	Sortwell, R. et al., "Chronic Intravenous Administration of Lentinan to the Rhesus Monkey", Toxicology Letters, Vol. 9, Pages 81-85 (1981)	
	8	Shimazu, H. et al., "Intravenous chronic toxicity of lentinan in rats: 6-month treatment and 3-month recovery", National Library of Medicine (PubMed), J Toxicol Sci, Pages 33-57 (1980)	
	9	Mehvar, R., "Recent Trends in the Use of Polysaccharides for Improved Delivery of Therapeutic Agents: Pharmacokinetic and Pharmacodynamic Perspectives", Current Pharmaceutical Biotechnology, Vol. 4, Pages 283-302 (2003)	
	10	Hanaue, H. et al., "Basic Studies on Oral Administration of Lentinan (I)", J. Jpn. Cancer Ther., Vol. 8, Pages 1566-1571 (1989)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/621,027
		Filing Date	July 16, 2003
		First Named Inventor	Nai-Kong Cheung
		Art Unit	1623
		Examiner Name	Jason H. Johnson
Sheet 2	of 2	Attorney Docket Number	639-B-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	11	Kidd, P., "The Use of Mushroom Glucans and Proteoglycans in Cancer Treatment", Alternative Medicine Review, Vol. 5, No. 1, Pages 4-27 (2000)	
	12	Hanaue, H. et al, "Effects of Oral Lentinan on T-Cell Subsets in Periphe Venous Blood", Clinical Therapeutics, Vol. 5 (1989)	
	13	Suzuki, M. et al, "Antitumor and Immunological Activity of Lentinan in Comparison with LPS", International Society of Pharmacology, Ltd., Pages 463-468 (1994)	
	14	Cheung, N.; Modak, S.; "Oral (1-3), (1-4)-B-D-Glucan Synergizes with Antiganglioside GD2 Monoclonal Antibody 3F8 in the Therapy of Neuroblastoma", Clinical Cancer Research, Vol. 8, Pages 1217-1223 (2002)	
	15	Chihara, G. et al., "Antitumor and Metastasis-Inhibitory Activities of Lentinan as an Immunomodulator: An Overview", Cancer Detection and Prevention Supplement, Vol. 1, Pages 423-443 (1987)	
	16	Mayer, L.; Shao, L., "Therapeutic Potential of Oral Tolerance", Nature Reviews Immunology, Vol. 4, Pages 407-419 (2004)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.